These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21470582)

  • 21. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA
    Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
    Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
    Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac dysfunction in clinical trials of trastuzumab.
    Page E; Assouline D; Brun O; Coeffic D; Fric D; Winckel P
    J Clin Oncol; 2002 Oct; 20(19):4119; author reply 4120. PubMed ID: 12351610
    [No Abstract]   [Full Text] [Related]  

  • 25. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer.
    Link JS; Waisman JR; Nguyen B; Jacobs CI
    Clin Breast Cancer; 2007 Oct; 7(10):779-83. PubMed ID: 18021479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.
    Taira Y; Shimoji Y; Nakasone T; Arakaki Y; Nakamoto T; Kudaka W; Aoki Y
    J Obstet Gynaecol Res; 2021 Feb; 47(2):833-837. PubMed ID: 33300217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
    Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
    J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E; Hall K
    Br J Nurs; 2009 Mar 26-Apr 8; 18(6):351-6, 358. PubMed ID: 19329899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
    Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab: serious neurological disorders and nasal perforations.
    Prescrire Int; 2007 Jun; 16(89):112. PubMed ID: 17582932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
    Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal steroids and septum perforation--an overlooked complication? A description of the course of events and a discussion of the causes.
    Cervin A; Andersson M
    Rhinology; 1998 Sep; 36(3):128-32. PubMed ID: 9830677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab in breast cancer: the best is yet to come?
    Puhalla S; Brufsky A
    Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
    [No Abstract]   [Full Text] [Related]  

  • 36. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab and breast cancer: the E2100 outlier.
    Fojo T; Wilkerson J
    Lancet Oncol; 2010 Dec; 11(12):1117-9. PubMed ID: 21126685
    [No Abstract]   [Full Text] [Related]  

  • 39. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
    Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.